Rapport Therapeutics, Inc. - Common Stock (RAPP) — AI analysis & news
Rapport Therapeutics, Inc. - Common Stock (RAPP) stock: 9 recent news items, slightly negative aggregate sentiment, AI analysis and market context on…
Current sentiment read
Across the last 9 indexed RAPP stories, aggregate finance-aware sentiment is slightly negative (-0.14 on a -1 to +1 scale).
Latest RAPP news
- Rapport Therapeutics CEO Abraham Ceesay sells $143,272 in stock By Investing.com - Investing.com Nigeria · Investing.com Nigeria
- Rapport Therapeutics CEO Abraham Ceesay sells $143,272 in stock By Investing.com - Investing.com UK · Investing.com UK
- How to buy Rapport Therapeutics (rRAPP) stock in Aruba? - Bitget · Bitget
- Rapport Therapeutics CEO Ceesay sells $86,565 in company stock - Investing.com India · Investing.com India
- Why is Rapport Therapeutics stock sliding today? By Investing.com - Investing.com South Africa · Investing.com South Africa
- Why is Rapport Therapeutics stock sliding today? - Investing.com · Investing.com
- Why is Rapport Therapeutics stock sliding today? By Investing.com - Investing.com India · Investing.com India
- Raymond James reiterates Strong Buy on Rapport Therapeutics stock By Investing.com - Investing.com India · Investing.com India
- Truist reiterates Buy on Rapport Therapeutics stock ahead of data By Investing.com - Investing.com UK · Investing.com UK
FAQ
What is the current sentiment for RAPP stock?
Aggregate finance-aware sentiment across the last 9 indexed RAPP news stories is slightly negative (-0.14 on a -1 to +1 scale).